title: Blockage of peripheral NPY Y1 and Y2 receptors modulates barorefex sensitivity of diabetic rats.
abstract: OBJECTIVE
  Abnormal baroreceptor reflex sensitivity (BRS) and elevated plasma neuropeptide Y (NPY) are prevalent in diabetic patients. The present study was conducted to determine whether NPY Y1 receptor (Y1R) and NPY Y2 receptor (Y2R) contribute to the regulatin of BRS in diabetic rats.
  
  
  METHODS
  Diabetes mellitus (DM) rats with hyperlipidemia were developed by an emulsion diet enriched with fat, sucrose and fructose followed by streptozocin (STZ). Y1R and Y2R specific antagonists (BIBP 3226 and BIIE 0246) were administered by a mini-osmotic pump. Systolic blood pressure (SBP), heart rate (HR), BRS and heart functions, as well as the plasma NPY and lipid level were measured after treatment for 4 weeks.
  
  
  RESULTS
  Both BIBP 3226 and BIIE 0246 treatment reversed the elevated total cholesterol (TC) and low density lipoprotein (LDL-C) level, and reduced high density lipoprotein (HDL-C) level in DM rats. BIIE 0246 may attenuate the increased triglyceride (TG) level in DM rats. In addition, neither BIBP 3226 nor BIIE 0246 treatment produced significant effects on BRS, SBP or HR (P>0.05) in DM rats, even after PE and SNP challenge. However, BIBP 3226 and BIIE 0246 further impaired LVSP, LVEDP, +dp/dtmax and -dp/dtmax.
  
  
  CONCLUSIONS
  This study provided us with the evidence that the inhibition of peripheral Y1R and Y2R did not affect impaired BRS but amplified the deterioration of the compromised cardiac function in STZ-induced DM rats with hyperlipidemia.
authors.affiliation: Department of Pharmacology, Harbin Medical University (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin, Heilongjiang Province, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Ning
authors.initials: N
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Xie
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Sun
authors.forename: Qing-Xin
authors.initials: QX
authors.lastname: Chen
authors.forename: Jian-Han
authors.initials: JH
authors.lastname: Ye
authors.forename: Ben-Zhi
authors.initials: BZ
authors.lastname: Cai
authors.forename: Bao-Feng
authors.initials: BF
authors.lastname: Yang
authors.forename: Jing
authors.initials: J
authors.lastname: Ai
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D017704:Baroreflex / Q000187:drug effects / Q000502:physiology*; D001552:Benzazepines / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D006339:Heart Rate / Q000187:drug effects; D006949:Hyperlipidemias / Q000150:complications / Q000378:metabolism / Q000473:pathology; D008297:Male; D009478:Neuropeptide Y / Q000097:blood; D009599:Nitroprusside / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: C092926:BIBP 3226; D001552:Benzazepines; D008078:Cholesterol, LDL; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; D014280:Triglycerides; C097212:neuropeptide Y-Y1 receptor; C095889:neuropeptide Y2 receptor; D009599:Nitroprusside; D010656:Phenylephrine; D001120:Arginine; D002784:Cholesterol; C403256:BIIE 0246